Syncor shows rebound with 1995 results
Nuclear medicine pharmacy firm Syncor reported solid financialresults for its 1995 fiscal year (end-December), offering furtherproof that the nuclear medicine industry's slump eased last year.The Chatsworth, CA, firm said that both revenues and
Nuclear medicine pharmacy firm Syncor reported solid financialresults for its 1995 fiscal year (end-December), offering furtherproof that the nuclear medicine industry's slump eased last year.The Chatsworth, CA, firm said that both revenues and earningswere up and the company had achieved its financial objectives.
For 1995, Syncor had revenues of $332.5 million, up 4% comparedwith $320 million in 1994. Net income last year stood at $4.7million, up sharply from $1.2 million the year before.
For the fourth quarter, Syncor reported net income of $1.1million on revenues of $85.1 million. In 1994, the company hada loss of $537,000 on sales of $81.7 million.
Syncor said that the improved numbers were due to cost controlprograms, a better product mix, and successful efforts to manageradiopharmaceutical pricing. Cardiology sales continue to driverevenue growth, with sales from cardiology products accountingfor 63% of the company's business in 1995, up from 56% in 1994.
Chest CT Study Shows Higher Emphysema Risk from Combination of Marijuana and Cigarette Smoking
November 28th 2023People who smoke marijuana and cigarettes have 12 times the risk for centrilobular emphysema than non-smokers, according to new computed tomography (CT) research presented at the annual Radiological Society of North America (RSNA) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Study Suggests CT-Guided Injections May Restore Sense of Smell in Patients with Long COVID
November 20th 2023Utilizing computed tomography (CT) guidance, researchers have found that performing a minimally invasive anesthetic injection into the stellate ganglia may help address parosmia due to COVID-19, according to study results that will be presented at the annual Radiological Society of North America (RSNA) conference next week.
